Advanced non-small cell lung cancer: The role of maintenance therapy

Anuj K. Agarwala, Nasser Hanna

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Platinum-based chemotherapy has been shown to provide survival benefits in advanced non-small cell lung cancer (NSCLC). Maintenance/consolidation chemotherapy in NSCLC has gained renewed interest with improved tolerability of chemotherapy and the addition of biologic agents. Various studies have evaluated the role of prolonged duration of chemotherapy as well as maintenance/ consolidation strategies with both chemotherapy and biologic agents. The available data at this time demonstrates that maintenance or consolidation therapy can improve progression free survival; however this does not result consistently in an improved overall survival. We review the literature with regard to duration of therapy and use of maintenance/consolidation therapy in advanced NSCLC.

Original languageEnglish
Pages (from-to)17-23
Number of pages7
JournalTherapeutic Advances in Medical Oncology
Volume2
Issue number1
DOIs
StatePublished - 2010

Fingerprint

Non-Small Cell Lung Carcinoma
Drug Therapy
Maintenance
Biological Factors
Consolidation Chemotherapy
Maintenance Chemotherapy
Therapeutics
Platinum
Disease-Free Survival

Keywords

  • Maintenance therapy
  • Non-small cell lung cancer
  • Overall survival
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Advanced non-small cell lung cancer : The role of maintenance therapy. / Agarwala, Anuj K.; Hanna, Nasser.

In: Therapeutic Advances in Medical Oncology, Vol. 2, No. 1, 2010, p. 17-23.

Research output: Contribution to journalArticle

@article{753abd3b49704ca6a1dc244ab65e195d,
title = "Advanced non-small cell lung cancer: The role of maintenance therapy",
abstract = "Platinum-based chemotherapy has been shown to provide survival benefits in advanced non-small cell lung cancer (NSCLC). Maintenance/consolidation chemotherapy in NSCLC has gained renewed interest with improved tolerability of chemotherapy and the addition of biologic agents. Various studies have evaluated the role of prolonged duration of chemotherapy as well as maintenance/ consolidation strategies with both chemotherapy and biologic agents. The available data at this time demonstrates that maintenance or consolidation therapy can improve progression free survival; however this does not result consistently in an improved overall survival. We review the literature with regard to duration of therapy and use of maintenance/consolidation therapy in advanced NSCLC.",
keywords = "Maintenance therapy, Non-small cell lung cancer, Overall survival, Targeted therapy",
author = "Agarwala, {Anuj K.} and Nasser Hanna",
year = "2010",
doi = "10.1177/1758834009351443",
language = "English",
volume = "2",
pages = "17--23",
journal = "Therapeutic Advances in Medical Oncology",
issn = "1758-8340",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Advanced non-small cell lung cancer

T2 - The role of maintenance therapy

AU - Agarwala, Anuj K.

AU - Hanna, Nasser

PY - 2010

Y1 - 2010

N2 - Platinum-based chemotherapy has been shown to provide survival benefits in advanced non-small cell lung cancer (NSCLC). Maintenance/consolidation chemotherapy in NSCLC has gained renewed interest with improved tolerability of chemotherapy and the addition of biologic agents. Various studies have evaluated the role of prolonged duration of chemotherapy as well as maintenance/ consolidation strategies with both chemotherapy and biologic agents. The available data at this time demonstrates that maintenance or consolidation therapy can improve progression free survival; however this does not result consistently in an improved overall survival. We review the literature with regard to duration of therapy and use of maintenance/consolidation therapy in advanced NSCLC.

AB - Platinum-based chemotherapy has been shown to provide survival benefits in advanced non-small cell lung cancer (NSCLC). Maintenance/consolidation chemotherapy in NSCLC has gained renewed interest with improved tolerability of chemotherapy and the addition of biologic agents. Various studies have evaluated the role of prolonged duration of chemotherapy as well as maintenance/ consolidation strategies with both chemotherapy and biologic agents. The available data at this time demonstrates that maintenance or consolidation therapy can improve progression free survival; however this does not result consistently in an improved overall survival. We review the literature with regard to duration of therapy and use of maintenance/consolidation therapy in advanced NSCLC.

KW - Maintenance therapy

KW - Non-small cell lung cancer

KW - Overall survival

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=77953447512&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953447512&partnerID=8YFLogxK

U2 - 10.1177/1758834009351443

DO - 10.1177/1758834009351443

M3 - Article

C2 - 21789123

AN - SCOPUS:77953447512

VL - 2

SP - 17

EP - 23

JO - Therapeutic Advances in Medical Oncology

JF - Therapeutic Advances in Medical Oncology

SN - 1758-8340

IS - 1

ER -